Company: Daiichi Sankyo
Job title: Senior Director, CMC Management & Operations
Dr. David A. Conlon is a Senior Director at Daiichi Sankyo, Inc (DSI) leading the US Chemistry, Manufacturing and Controls Management & Operations (CMC M & O) function. The DSI CMC M & O group is a team of technical subject matter experts responsible for the development and implementation of the strategy to bring new medicines to patients.
Dr. Conlon has been involved in pharmaceutical research and development for 30 years. Prior to joining Daiichi Sankyo, Inc, he held positions of increasing responsibility in the Chemical & Synthetic Development Department at Bristol-Myers Squibb and the Process Research Department at Merck & Co. Inc. Dr. Conlon was a key member of the Merck technical teams that transferred the asthma drug Singulair® and the antifungal Cancidas® from the research laboratories to the manufacturing division.
Dr. Conlon earned his B.S. degree in chemistry from Union College in Schenectady, NY and his Ph.D. from the University of Rochester. Prior to entering graduate school, he was employed by General Electric at their Corporate Research and Development Center.
Dr. Conlon has experience in all aspects of the process design, optimization and development of synthetic routes to pharmaceutical intermediates and active pharmaceutical ingredients. He is the author or co-author on over 60 publications, 4 book chapters and 8 U.S. patents. Dr. Conlon is also active in the scientific community, having served as a member of the Editorial Advisory Board (EAB) for the American Chemical Society (ACS) Journal Organic Process Research & Development (OPR&D) and a Councilor on the Executive Committee of the ACS Division of Organic Chemistry (DOC).